摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

4-羟甲基-1-萘甲酸甲酯 | 105904-00-5

中文名称
4-羟甲基-1-萘甲酸甲酯
中文别名
——
英文名称
4-carbomethoxy-1-naphthylmethanol
英文别名
methyl 4-hydroxymethyl-1-naphthoate;methyl 4-hydroxymethylnaphthoate;methyl 4-(hydroxymethyl)-1-naphthalenecarboxylate;Methyl 4-(hydroxymethyl)naphthalene-1-carboxylate
4-羟甲基-1-萘甲酸甲酯化学式
CAS
105904-00-5
化学式
C13H12O3
mdl
——
分子量
216.236
InChiKey
DDUCEEWYDOABBS-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    2.1
  • 重原子数:
    16
  • 可旋转键数:
    3
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.15
  • 拓扑面积:
    46.5
  • 氢给体数:
    1
  • 氢受体数:
    3

SDS

SDS:3d1d2fe497554fde3f7959071d006ce7
查看

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量
  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    描述:
    4-羟甲基-1-萘甲酸甲酯manganese(IV) oxide 、 sodium carbonate 作用下, 以 二氯甲烷 为溶剂, 反应 18.0h, 生成 4-甲酰基萘-1-羧酸
    参考文献:
    名称:
    Optimization of Alkylidene Hydrazide Based Human Glucagon Receptor Antagonists. Discovery of the Highly Potent and Orally Available 3-Cyano-4-hydroxybenzoic Acid [1-(2,3,5,6-Tetramethylbenzyl)-1H-indol-4-ylmethylene]hydrazide
    摘要:
    Highly potent human glucagon receptor (hGluR) antagonists have been prepared employing both medicinal chemistry and targeted libraries based on modification of the core (proximal) dimethoxyphenyl group, the benzyl ether linkage, as well as the (distal) benzylic aryl group of the lead 2, 3-eyano-4-hydroxybenzoic acid (3,5-dimethoxy-4-isopropylbenzyloxybenzylidene)hydrazide. Electron-rich proximal aryl moieties such as mono- and dimethoxy benzenes, naphthalenes, and indoles were found to be active. The SAR was found to be quite insensitive regarding the linkage to the distal aryl group, since long and short as well as polar and apolar linkers gave highly potent compounds. The presence of a distal aryl group was not crucial for obtaining high binding affinity to the hGluR. In many cases, however, the affinity could be further optimized with substituted distal aryl groups. Representative compounds have been tested for in vitro metabolism, and structure-metabolism relationships are described. These efforts lead to the discovery of 74, NNC 25-2504, 3-cyano-4-hydroxybenzoic acid [1-(2,3,5,6-tetramethylbenzyl)-1H-indol-4-ylmethylenelhydrazide, with low in vitro metabolic turnover. 74 was a highly potent noncompetitive antagonist of the human glucagon receptor (IC50 = 2.3 nM, K-B = 760 pM) and of the isolated rat receptor IC50 = 430 pM, K-B = 380 pM). Glucagon-stimulated glucose production from isolated primary rat hepatocytes was inhibited competitively by 74 (K-i = 14 nM). This compound was orally available in dogs (F-po = 15%) and was active in a glucagon-challenged rat model of hyperglucagonemia and hyperglycemia.
    DOI:
    10.1021/jm0208572
  • 作为产物:
    描述:
    4-(溴甲基)萘-1-甲腈sodium hydroxide 作用下, 以 乙醚 为溶剂, 反应 120.0h, 生成 4-羟甲基-1-萘甲酸甲酯
    参考文献:
    名称:
    苯乙酸和 3-苯丙酸的取代 1-萘基甲酯的光化学:自由基对、离子对和 Marcus 电子转移
    摘要:
    苯乙酸 (3a-k) 和 3-苯基丙酸 (5a-c) 酸的环取代 1-萘基甲酯已在甲醇溶剂中光解。这些反应的主要产物来自两个关键中间体,即 1-萘甲基自由基/酰氧基自由基对和 1-萘甲基阳离子/羧酸根阴离子对。在从酰氧基中失去二氧化碳后,自由基对导致形成笼内偶联产物 8a-k 和 10a-c。离子对导致甲基醚 6a-k 和羧酸 7 和 9
    DOI:
    10.1021/ja00059a012
点击查看最新优质反应信息

文献信息

  • Glucagon antagonists/inverse agonists
    申请人:Novo Nordisk A/S
    公开号:US06613942B1
    公开(公告)日:2003-09-02
    Non-peptide compounds comprising a central hydrazide motif and methods for the synthesis thereof are disclosed. The compounds act to antagonize the action of the glucagon peptide hormone.
    本发明公开了包含中央腙基结构的非肽化合物及其合成方法。这些化合物具有拮抗胰高血糖素肽激素作用的作用。
  • Pd-Catalyzed Dearomative Allylation of Benzyl Phosphates
    作者:Masaaki Komatsuda、Kei Muto、Junichiro Yamaguchi
    DOI:10.1021/acs.orglett.8b01807
    日期:2018.7.20
    Dearomative C–C bond formation of benzyl phosphates has been developed. In the presence of a palladium/PAr3 catalyst, benzyl phosphates reacted with allyl borates to generate the allylated product in a dearomative fashion. The resulting dearomatized molecules were successfully derivatized by Simmons–Smith cyclopropanation and oxidation.
    已经开发出苄基磷酸的脱芳香族C–C键形成。在钯/ PAr 3催化剂的存在下,磷酸苄酯与硼酸烯丙酯反应,以脱芳族方式生成烯丙基化产物。产生的脱芳烃分子已通过Simmons-Smith环丙烷化和氧化作用成功衍生。
  • [EN] GLUCAGON ANTAGONISTS/INVERSE AGONISTS<br/>[FR] ANTAGONISTES/AGONISTES INVERSES DU GLUCAGON
    申请人:NOVO NORDISK AS
    公开号:WO1999001423A1
    公开(公告)日:1999-01-14
    Non-peptide compounds comprising a central hydrazide motif and methods for the synthesis thereof. The compounds act to antagonize the action of the glucagon peptide hormone.
    非肽化合物包含一个中心肼基结构,并且其合成方法。这些化合物作用是拮抗胰高血糖素肽激素的作用。
  • Aminoethanol derivatives
    申请人:——
    公开号:US20040127574A1
    公开(公告)日:2004-07-01
    The present invention provides a pharmaceutical agent having cholesteryl ester transfer protein inhibitory action and useful as a blood lipid lowering agent and the like. The present invention relates to a compound represented by the formula 1 wherein Ar 1 is an aromatic ring group optionally having substituents, Ar 2 is an aromatic ring group having substituents, OR″ is an optionally protected hydroxyl group, R is an acyl group, R′ is a hydrogen atom or a hydrocarbon group optionally having substituents, or a salt thereof, and a pharmaceutical composition containing a compound of the formula (I) or a salt thereof or a prodrug thereof.
    本发明提供了一种具有胆固醇酯转移蛋白抑制作用的药物剂,可用作降低血脂等方面的药物。本发明涉及一种由式1表示的化合物,其中Ar1是一个带有取代基的芳香环基团,Ar2是一个带有取代基的芳香环基团,OR″是一个可选保护的羟基,R是一个酰基,R′是一个氢原子或一个可选带有取代基的碳氢基团,或其盐,以及含有式(I)的化合物或其盐或前药的药物组合物。
  • AMINOETHANOL DERIVATIVES
    申请人:Takeda Chemical Industries, Ltd.
    公开号:EP1362846A1
    公开(公告)日:2003-11-19
    The present invention provides a pharmaceutical agent having cholesteryl ester transfer protein inhibitory action and useful as a blood lipid lowering agent and the like. The present invention relates to a compound represented by the formula wherein Ar1 is an aromatic ring group optionally having substituents, Ar2 is an aromatic ring group having substituents, OR'' is an optionally protected hydroxyl group, R is an acyl group, R' is a hydrogen atom or a hydrocarbon group optionally having substituents, or a salt thereof, and a pharmaceutical composition containing a compound of the formula (I) or a salt thereof or a prodrug thereof.
    本发明提供了一种具有胆固醇酯转移蛋白抑制作用的药剂,可用作降血脂药等。本发明涉及一种由式表示的化合物 其中 Ar1 是可选具有取代基的芳香环基,Ar2 是可选具有取代基的芳香环基,OR''是可选保护的羟基,R 是酰基,R'是氢原子或可选具有取代基的烃基,或其盐,以及含有式(I)化合物或其盐或其原药的药物组合物。
查看更多